BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29706040)

  • 1. [Low serum testosterone level does not predict bone metastasis of prostate cancer].
    Li XB; Zhang L; Rao TW; Chen J; Leng YJ; Huang P
    Zhonghua Nan Ke Xue; 2017 Mar; 23(3):212-216. PubMed ID: 29706040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis.
    Chen SS; Chen KK; Lin AT; Chang YH; Wu HH; Chang LS
    BJU Int; 2002 May; 89(7):710-3. PubMed ID: 11966629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigative clinical study on prostate cancer part IX and X: estradiol and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
    Porcaro AB; Ghimenton C; Petrozziello A; Sava T; Migliorini F; Romano M; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C
    Anticancer Res; 2012 Oct; 32(10):4523-32. PubMed ID: 23060581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis of prostate cancer and subsequent cluster selection of the patient population undergoing standard radical prostatectomy.
    Porcaro AB; Migliorini F; Petrozziello A; Sava T; Romano M; Caruso B; Cocco C; Ghimenton C; Zecchinini Antoniolli S; Lacola V; Rubilotta E; Monaco C; Comunale L
    Urol Int; 2013; 90(1):45-55. PubMed ID: 23128438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigative clinical study on prostate cancer part VI: Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
    Porcaro AB; Migliorini F; Petrozziello A; Sava T; Romano M; Caruso B; Cocco C; Ghimenton C; Zecchinini Antoniolli S; Lacola V; Rubilotta E; Monaco C; Comunale L
    Urol Int; 2012; 88(2):150-7. PubMed ID: 22205171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of hypothalamic-pituitary-testicular axis hormones in men with or without prostate cancer or atypical small acinar proliferation.
    Schmitt Cda S; Rhoden EL; Almeida GL
    Clinics (Sao Paulo); 2011; 66(2):183-7. PubMed ID: 21484031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Along the pituitary-testis-prostate axis, serum total testosterone is a significant preoperative variable independently contributing to separating the prostate cancer population into prostatectomy Gleason score groups.
    Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Cocco C; Romano M; Artibani W
    Anticancer Res; 2012 Nov; 32(11):5015-22. PubMed ID: 23155273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigative clinical study on prostate cancer part VII: prolactin and the pituitary-testis-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
    Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
    Anticancer Res; 2011 Nov; 31(11):3913-20. PubMed ID: 22110219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements].
    Bantis A; Zissimopoulos A; Athanasiadou P; Gonidi M; Agelonidou E; Strataki A; Matthaios D; Tsartsarakis A
    Hell J Nucl Med; 2007; 10(1):56-61. PubMed ID: 17450256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.
    Han KS; Hong SJ
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1769-76. PubMed ID: 24858569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-grade prostate cancer is associated with low serum testosterone levels.
    Schatzl G; Madersbacher S; Thurridl T; Waldmüller J; Kramer G; Haitel A; Marberger M
    Prostate; 2001 Apr; 47(1):52-8. PubMed ID: 11304729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigative clinical study on prostate cancer part VIII: prolactin hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
    Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
    Anticancer Res; 2012 Apr; 32(4):1499-506. PubMed ID: 22493393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A possible relationship between serum sex hormones and benign prostatic hyperplasia/lower urinary tract symptoms in men who underwent transurethral prostate resection.
    Wu Y; Pan H; Wang WM; Xu D; Zhang L; Gu ZQ; Bai Q; Qi J; Huang HF
    Asian J Androl; 2017; 19(2):230-233. PubMed ID: 26763548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
    Schatzl G; Marberger M; Remzi M; Grösser P; Unterlechner J; Haidinger G; Zidek T; Preyer M; Micksche M; Gsur A
    Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum total testosterone is a significant preoperative variable independently contributing to separating the prostate cancer population into prostatectomy Gleason score groups.
    Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Cocco C; Romano M; Cavalleri S; Artibani W
    Urol Int; 2013; 91(1):55-61. PubMed ID: 23751412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No association of serum gonadal or pituitary hormones with prognostic parameters in stages T1 to T3 PN0M0 prostate cancer.
    Fodstad P; Bjøro T; Torlakovic G; Fossa SD
    J Urol; 2002 Sep; 168(3):1188-92. PubMed ID: 12187265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
    Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.